Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Oct 13 · below the Ichimoku cloud · RSI 60 · MACD above its signal · 7% above its 52-week low
None of the 29 investors followed here reported a position in 1099.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 1099.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for 1099.HK.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 7.5 | 1.2 | -4.4 | -8.6 | -8.4 | -6.0 | 9.2 | -10.8 | -4.1 | 5.0 | −19.7% | ||
| 2025 | -4.2 | -4.7 | -7.9 | 1.7 | 3.6 | -3.3 | 2.6 | -1.0 | -1.8 | 5.6 | 3.5 | -3.0 | −9.4% |
| 2024 | 0.5 | 6.8 | -8.7 | -1.0 | 6.9 | -2.1 | -11.5 | -1.0 | 14.4 | -7.0 | 5.0 | 5.7 | +4.9% |
| 2023 | -3.1 | 9.3 | 13.1 | 16.8 | -7.6 | -4.5 | -0.2 | -7.0 | -0.2 | -17.6 | 3.6 | 5.5 | +3.1% |
| 2022 | 2.5 | 8.6 | -5.3 | 1.6 | 7.2 | -2.3 | -5.4 | -2.9 | -10.0 | -5.0 | 23.3 | 7.6 | +17.0% |
| 2021 | 0.6 | -4.1 | 3.6 | 28.1 | 9.5 | -12.5 | -11.7 | -2.1 | 1.6 | -8.6 | -8.7 | 0.1 | −9.9% |
| 2020 | -10.4 | -5.7 | -27.5 | 20.4 | -9.2 | 4.1 | -7.0 | 3.4 | -14.8 | 9.0 | 8.1 | -1.8 | −33.8% |
| 2019 | 6.5 | -0.4 | -6.3 | -5.8 | -4.4 | -6.6 | 6.2 | -2.9 | -13.4 | 14.7 | -8.2 | 10.1 | −13.5% |
| 2018 | 2.2 | 0.0 | 13.7 | -15.8 | 5.3 | -9.5 | 5.2 | 17.6 | -1.9 | -1.3 | 2.0 | -14.7 | −2.7% |
| 2017 | 11.4 | 0.8 | 0.4 | -3.2 | 2.0 | -0.8 | -7.2 | 7.9 | -2.7 | 1.5 | -12.0 | 10.1 | +5.8% |
| 2016 | -12.2 | 4.0 | 23.4 | -5.0 | 8.1 | 2.6 | 1.6 | 5.9 | -6.3 | 1.3 | -4.1 | -11.7 | +2.7% |
| 2015 | 3.3 | -4.2 | 16.6 | 16.6 | 0.3 | -6.9 | -13.5 | -1.5 | -7.7 | 18.5 | 1.4 | -4.5 | +13.3% |
| 2014 | -1.6 | -1.6 | -1.4 | -4.0 | 3.2 | 1.9 | 6.5 | 18.4 | 5.0 | 6.7 | -4.6 | -5.0 | +23.4% |
| 2013 | -2.1 | 3.2 | 2.2 | -8.0 | -8.9 | -7.2 | 8.8 | -8.3 | 0.1 | 7.9 | 9.8 | -3.5 | −8.2% |
| 2012 | -1.5 | 14.8 | 2.8 | -6.2 | -13.6 | 21.2 | 7.0 | 8.1 | 0.8 | 4.8 | -7.7 | 0.8 | +30.0% |
| 2011 | 1.7 | 2.7 | -2.5 | -2.5 | 3.7 | -6.3 | -13.2 | -17.4 | 10.6 | 3.1 | -14.0 | 1.4 | −31.1% |
| 2010 | 6.4 | 19.3 | -0.1 | 2.1 | -13.5 | -6.8 | 1.0 | 2.1 | 8.1 | -5.0 | -6.7 | -4.6 | −1.6% |
| 2009 | 43.6 | -3.2 | 0.9 | +40.3% |
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices Distribution segment distributes medical devices, as well as provides installation and maintenance services. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the distribution of laboratory supplies; manufacture and distribution of chemical reagents; and production and sale of pharmaceutical products. The company rents and manages properties; distributes medical instruments and equipment, Chinese herbal medicines, antibiotics, and biological products; and offers information technology, investment, goods and technology import and export, business consulting, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services. It also manages medical project investment, consulting, and technology training activities; and manufactures medicines. Sinopharm Group Co. Ltd. was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Buy / hold / sell counts
No recent headlines.